UK approves GSK's Covid antibody drug that slashes risk of death and hospitalisation

Sotrovimab, sold under the brand name Xevudy, cuts the risk of hospitalisation by 79 per cent among those at risk from the virus. But there are fears it may be less effective against Omicron.

from Health News | Mail Online https://ift.tt/31iDxbb

Comentarii

Postări populare de pe acest blog

Telehealth hubs offer care options for people living on the edge the virtual world

Overuse on cattle feedlots is a key factor in antibiotic resistance, report says

Bringing Your Ballpark Food Favorites Home